BCYC
Bicycle Therapeutics plc - ADR
After-Market
3.60
Bicycle Therapeutics plc - ADR Profile
About
Info & Links
CEO
Kevin Lee
Headquarters
CAMBRIDGE, X0 CB21 6GS, UNITED KINGDOM
Industry
Sector
Website
Auditor
PricewaterhouseCoopers LLP
Share holders
48
Employees
288
Bicycle Therapeutics plc - ADR Statistics
Valuation Measures
Market Capitalization2
251.62M
Enterprise Value
-258.43M
Enterprise Value/EBITDA(ttm)
1.26
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
4.15
Price to Book(mrq)
0.50
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-311.11%
Profit Margin(ttm)
-3851.29%
Return on Equity(ttm)
-33.22%
Return on Invested Capital(ttm)
-33.70%
Return on Assets(ttm)
-27.79%
Income Statement
Revenue(ttm)
61.20M
Revenue Per Share(ttm)
0.87
Gross Profit(ttm)
61.20M
EBITDA(ttm)3
-205.01M
Net Income Available to Common(ttm)
-190.41M
Diluted EPS(ttm)
-2.73
Share Statistics
Beta (5Y Monthly)
1.54
52-Week Change
-49.51%
S&P 500 52-Week Change
17.10%
S&P 500 Member
No
Stock Optionable
Yes
Total Shares Outstanding1
69.99M
Dividend Yield
0.00%
Float4
54.59M
% Held by Insiders
22.00%
% Held by Institutions
86.15%
Balance Sheet
Total Cash(mrq)
510.05M
Total Cash Per Share(mrq)
7.29
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
12.08%
Quick Ratio(mrq)
12.08%
Book Value Per Share(mrq)
7.31
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.66
Free Cash Flow(ytd)
-116.51M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.